| Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm |
NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. |
prnewswire.com |
2025-05-14 19:50:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript |
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Mike Milligan - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Yatin Suneja - Guggenheim Graig Suvannavejh - Mizuho Securities John Boyle - William Blair Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-12 23:18:22 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runway extended into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass. |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. |
globenewswire.com |
2025-04-28 11:00:00 |
Czytaj oryginał (ang.) |
| NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Investors with Losses Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO"). |
accessnewswire.com |
2025-04-08 11:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141583&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-07 20:15:00 |
Czytaj oryginał (ang.) |
| NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) and certain of its officers. |
globenewswire.com |
2025-04-07 20:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion. |
Investors can contact the law firm at no cost to learn more about recovering their losses |
globenewswire.com |
2025-04-07 19:58:00 |
Czytaj oryginał (ang.) |
| NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline |
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141539&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-07 17:45:00 |
Czytaj oryginał (ang.) |
| NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm |
LOS ANGELES--(BUSINESS WIRE)--NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm. |
businesswire.com |
2025-04-07 16:32:00 |
Czytaj oryginał (ang.) |
| Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class Action - NMRA |
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141431&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| FINAL REMINDER NMRA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Neumora Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit |
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO"). |
accessnewswire.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK , April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-04-07 09:45:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA |
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141379&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-06 22:00:00 |
Czytaj oryginał (ang.) |
| NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA |
NEW YORK, April 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora's September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. |
globenewswire.com |
2025-04-06 21:41:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline |
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141333&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-06 15:13:00 |
Czytaj oryginał (ang.) |
| NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit |
RADNOR, Pa., April 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora's initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April 7, 2025. |
globenewswire.com |
2025-04-06 15:02:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA |
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141329&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-06 14:59:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA |
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=141325&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-04-06 14:19:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NMRA |
NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / NEW YORK, April 6, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-04-06 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA) Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. |
accessnewswire.com |
2025-02-27 22:00:00 |
Czytaj oryginał (ang.) |
| Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132807&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 18:30:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132788&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 17:30:00 |
Czytaj oryginał (ang.) |
| NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm |
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. So what: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2025-02-27 17:17:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. |
globenewswire.com |
2025-02-27 14:43:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NMRA |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132707&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 12:15:00 |
Czytaj oryginał (ang.) |
| A Securities Fraud Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025. |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132629&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-27 09:25:00 |
Czytaj oryginał (ang.) |
| NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO"). |
accessnewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
prnewswire.com |
2025-02-27 07:45:00 |
Czytaj oryginał (ang.) |
| Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132585&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 23:15:00 |
Czytaj oryginał (ang.) |
| Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses |
SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023. Neumora is a clinical-stage biopharmaceutical company. |
prnewswire.com |
2025-02-26 22:46:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132558&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 22:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-26 22:00:00 |
Czytaj oryginał (ang.) |
| Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132542&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 21:30:00 |
Czytaj oryginał (ang.) |
| ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ:NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
accessnewswire.com |
2025-02-26 21:00:00 |
Czytaj oryginał (ang.) |
| Investors in Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights – NMRA |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). |
globenewswire.com |
2025-02-26 15:32:00 |
Czytaj oryginał (ang.) |
| Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132488&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 15:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ:NMRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. |
accessnewswire.com |
2025-02-26 15:15:00 |
Czytaj oryginał (ang.) |
| Lost Money on Neumora Therapeutics, Inc. (NMRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=132450&wire=1 or contact Joseph E. Levi, Esq. |
accessnewswire.com |
2025-02-26 13:30:00 |
Czytaj oryginał (ang.) |
| Neumora Stock Hits Record Low on Depression Drug Study Failure |
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies. |
zacks.com |
2025-01-03 12:20:46 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA |
LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA. |
businesswire.com |
2025-01-02 20:40:00 |
Czytaj oryginał (ang.) |
| Neumora's depression drug fails trial, sinking shares |
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. |
youtube.com |
2025-01-02 17:15:13 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints |
Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3 KOASTAL-1 study. The study, one of three replicate trials in Neumora's KOASTAL program, did not meet its primary endpoint of improvement in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) after six weeks. |
proactiveinvestors.com |
2025-01-02 13:19:15 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals |
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its goals. |
investopedia.com |
2025-01-02 12:55:59 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals |
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials |
marketwatch.com |
2025-01-02 12:27:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops |
Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies. The post Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops appeared first on Investor's Business Daily. |
investors.com |
2025-01-02 11:00:03 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics' depression drug fails to meet main goal of late-stage study |
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study. |
reuters.com |
2025-01-02 09:18:43 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder |
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo |
globenewswire.com |
2025-01-02 09:00:00 |
Czytaj oryginał (ang.) |
| Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck |
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise. |
seekingalpha.com |
2024-12-24 15:11:23 |
Czytaj oryginał (ang.) |
| This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho |
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year. |
marketwatch.com |
2024-11-13 13:03:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript |
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – President and Chief Executive Officer Josh Pinto – Chief Financial Officer Rob Lenz – Head of Research and Development Conference Call Participants Julian Pino – Stifel Brian Abrahams – RBC Capital Markets Myles Minter – William Blair Charles Wang – Mizuho Douglas Tsao – H.C. Wainwright Charlie Yang – Bank of America Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-11-12 13:50:34 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update |
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 |
globenewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics to Participate in Upcoming Conferences in November |
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November: |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders |
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET |
globenewswire.com |
2024-08-14 11:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation |
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response |
globenewswire.com |
2024-06-20 11:00:00 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression |
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study |
globenewswire.com |
2024-05-14 11:00:00 |
Czytaj oryginał (ang.) |
| NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 |
Neumora Therapeutics (NASDAQ: NMRA ) just reported results for the first quarter of 2024. Neumora Therapeutics reported earnings per share of -34 cents. |
investorplace.com |
2024-05-07 17:54:08 |
Czytaj oryginał (ang.) |
| Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update |
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 |
globenewswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug |
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news. |
zacks.com |
2024-04-16 16:31:06 |
Czytaj oryginał (ang.) |